Küsimused
| Dokumendiregister | Sotsiaalministeerium |
| Viit | 1.5-1.1/1532-1 |
| Registreeritud | 13.06.2024 |
| Sünkroonitud | 18.06.2024 |
| Liik | Sissetulev kiri |
| Funktsioon | 1.5 Asjaajamine. Info- ja kommunikatsioonitehnoloogia arendus ja haldus |
| Sari | 1.5-1.1 Teabenõuded, märgukirjad, selgitustaotlused |
| Toimik | 1.5-1.1/2024 |
| Juurdepääsupiirang | Avalik |
| Adressaat | Agency for Health Technology Assessment and Tariff System |
| Saabumis/saatmisviis | Agency for Health Technology Assessment and Tariff System |
| Vastutaja | Ulla Raid (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Tervisesüsteemi arendamise osakond) |
| Originaal | Ava uues aknas |
| Taotle dokumendi eemaldamist või parandamist |
Failid
Dear Sirs,
according to the preparation of analytics materials to consider changes in national legislation, We would like to kindly ask you to answer a few questions related to the health technology assessment system. If the answer to any of the questions is on your institution's
website or in a legal act, please indicate the source in the form of a link (hyperlink).
Is an clinical or economical effectiveness analysis carried out in your country for drugs newly included in the reimbursement system? If yes, please specify.
Is there a predetermined value for the cost-effectiveness threshold (the ratio of costs to health effects) in your country?
If yes, please indicate how it is calculated and whether there is any variation due to the type of technology being assessed or the nature of the target population.
In your country, are marketing authorization holders that apply for inclusion of a drug in the reimbursement system obliged to pay a fee for preparing an HTA analysis (clinical effectiveness, cost-effectiveness analysis, budget impact analysis or verification
analysis) by central/governmental institutions?
If yes, please indicate the amount and any discounts.
You are kindly requested to respond by June 19, 2024.
Kind regards
Michał Kazimierz Skroński
|
Senior HTA Specialist Department of Analysis and Medical Funds President’s Office
|
|
|
Agency for Health Technology Assessment and Tariff System ul. Przeskok 2; 00-032 Warsaw +48 22 101 46 48
|
|
